Download PDF
CC BY-NC-ND 4.0 · The Arab Journal of Interventional Radiology 2017; 1(02): 64-67
DOI: 10.4103/AJIR.AJIR_10_17
Original Article

Staged Radiofrequency Ablation and Surgical Resection for Multiple Lung Metastases of Germ Cell Tumors

Sebastian Tavolaro
Department of Radiology, Tenon Hospital, 75020 Paris, France
,
Guilhem Roubaud
Department of Oncology, Institut Bergonié, 33076 Bordeaux, France
,
Nadine Houédé
Department of Oncology, CHU Nimes, 30029 Nîmes, France
,
Jacques Jougon
Department of Thoracic Surgery, Haut Leveque Hospital, CHU de Bordeaux, 33076 Pessac, France
,
François H. Cornelis
Department of Radiology, Tenon Hospital, 75020 Paris, France
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Purpose: To evaluate the morbidity and efficacy of percutaneous radiofrequency ablation (RFA) performed before surgical resection for multiple residual lung metastases of germ cell tumors with negative tumor markers. Materials and Methods: This Review Board-approved retrospective study was carried out on five consecutive patients (mean age: 31 years, range: 22–41) treated successively with percutaneous RFA and surgery for multiple lung metastases of germ cell tumors. Mean number of lung metastases before treatment was 9.4. Staged procedures were performed on an average of 7.2 months (range: 1–16) after the primitive tumor resection. Results: The median clinical and imaging follow-up was 26 months (range: 24–36). Percutaneous RFA was technically feasible in one session under general anesthesia and CT guidance in all cases. On average, 2.8 tumors were ablated per patient (range: 1–6), and three of five procedures were bilateral. Three patients developed pneumothorax requiring drainage, but no severe complications were reported. Mean time between RFA and surgical resection of residual tumors was 2.5 months (range: 1–5). No local recurrences were noted, but one patient died due to metastatic evolution. Conclusion: Staged percutaneous RFA and surgical resection could be efficient with low morbidity for the management of multiple lung metastases of germ cell tumors.

Germ cell tumor - lung metastasis - radiofrequency ablation - surgery


Publication History

Article published online:
10 April 2021

© 2017. The Arab Journal of Interventional Radiology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990;8:1777-81.
  • 2 Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 1990;8:1683-94.
  • 3 Steyerberg EW, Keizer HJ, Zwartendijk J, Van Rijk GL, Van Groeningen CJ, Habbema JD, et al. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: A multivariate analysis. Br J Cancer 1993;68:195-200.
  • 4 Masterson TA, Carver BS, Shayegan B, Feldman DR, Motzer RJ, Bosl GJ, et al. Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. Urology 2012;79:1079-84.
  • 5 Abbas G, Schuchert MJ, Pennathur A, Gilbert S, Luketich JD. Ablative treatments for lung tumors: Radiofrequency ablation, stereotactic radiosurgery, and microwave ablation. Thorac Surg Clin 2007;17:261-71.
  • 6 de Baère T, Palussière J, Aupérin A, Hakime A, Abdel-Rehim M, Kind M, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: Prospective evaluation. Radiology 2006;240:587-96.
  • 7 de Baere T, Tselikas L, Gravel G, Deschamps F. Lung ablation: Best practice/results/response assessment/role alongside other ablative therapies. Clin Radiol 2017. pii: S0009-926030033-8.
  • 8 de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, et al. Radiofrequency ablation is a valid treatment option for lung metastases: Experience in 566 patients with 1037 metastases. Ann Oncol 2015;26:987-91.
  • 9 Cannella M, Cornelis F, Descat E, Ferron S, Carteret T, Castagnède H, et al. Bronchopleural fistula after radiofrequency ablation of lung tumours. Cardiovasc Intervent Radiol 2011;34 Suppl 2:S171-4.
  • 10 Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria – A 10-year update. Radiology 2014;273:241-60.
  • 11 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
  • 12 Palussière J, Gómez F, Cannella M, Ferron S, Descat E, Fonck M, et al. Single-session radiofrequency ablation of bilateral lung metastases. Cardiovasc Intervent Radiol 2012;35:852-9.
  • 13 Kashima M, Yamakado K, Takaki H, Kodama H, Yamada T, Uraki J, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: A single center's experiences. AJR Am J Roentgenol 2011;197:W576-80.